Suppr超能文献

2017 年丙型肝炎病毒治愈经济学指南

A Guide to the Economics of Hepatitis C Virus Cure in 2017.

机构信息

Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA; Department of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA.

出版信息

Infect Dis Clin North Am. 2018 Jun;32(2):447-459. doi: 10.1016/j.idc.2018.02.013.

DOI:10.1016/j.idc.2018.02.013
PMID:29778265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6085105/
Abstract

This commentary reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost effectiveness and affordability stands front and center as one of the leading obstacles to elimination.

摘要

本评论回顾了成本效益的核心原则，并将其应用于美国丙型肝炎病毒治疗的快速发展背景。本文提供了证据基础，表明丙型肝炎病毒治疗具有良好的经济价值，即使治疗费用昂贵，即使治疗的是丙型肝炎病毒再感染风险高的吸毒者。药物价格已经下降，但高价格仍然限制了获得治疗的机会。在消除丙型肝炎病毒的过程中，成本效益和可负担性之间的差距成为主要障碍之一。

相似文献

1
A Guide to the Economics of Hepatitis C Virus Cure in 2017.
Infect Dis Clin North Am. 2018 Jun;32(2):447-459. doi: 10.1016/j.idc.2018.02.013.
2
Localized US Efforts to Eliminate Hepatitis C.
Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009.
3
Hepatitis C eradication: A long way to go.
World J Gastroenterol. 2015 Nov 21;21(43):12510-2. doi: 10.3748/wjg.v21.i43.12510.
4
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.
5
The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.
6
Pathways to the elimination of hepatitis C: prioritising access for all.
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1023-1026. doi: 10.1080/17512433.2017.1383894.
7
Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
Expert Rev Gastroenterol Hepatol. 2016 Nov;10(11):1227-1234. doi: 10.1080/17474124.2016.1234375. Epub 2016 Sep 16.
8
Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.
9
[Hepatitis C: cost of eradication ].
Rev Med Suisse. 2014 Jan 29;10(415):306-7.
10
The economics of hepatitis C virus.
Clin Liver Dis. 2006 Nov;10(4):717-34. doi: 10.1016/j.cld.2006.08.026.

引用本文的文献

1
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317. doi: 10.1016/S2468-1253(21)00397-6. Epub 2022 Jan 10.
2
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
J Manag Care Spec Pharm. 2021 Oct;27(10):1388-1402. doi: 10.18553/jmcp.2021.27.10.1388.
3
Coordination, Cost, and Changing Epidemiology-Considerations in the Hepatitis C Care Cascade.
Hepatol Commun. 2021 Feb 28;5(3):355-357. doi: 10.1002/hep4.1667. eCollection 2021 Mar.
4
Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities.
Am J Manag Care. 2019 Aug;25(8):369-374.

本文引用的文献

1
The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.
Open Forum Infect Dis. 2017 Dec 8;5(1):ofx267. doi: 10.1093/ofid/ofx267. eCollection 2018 Jan.
2
Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.
Clin Infect Dis. 2018 Jan 18;66(3):376-384. doi: 10.1093/cid/cix798.
3
When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.
PLoS Med. 2017 Oct 2;14(10):e1002397. doi: 10.1371/journal.pmed.1002397. eCollection 2017 Oct.
4
Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
J Leg Med. 2017 Jan-Jun;37(1-2):21-64. doi: 10.1080/01947648.2017.1284700.
5
High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
Int J Drug Policy. 2017 Sep;47:196-201. doi: 10.1016/j.drugpo.2017.07.021. Epub 2017 Aug 12.
6
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3.
7
Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States.
J Clin Transl Hepatol. 2017 Mar 28;5(1):16-22. doi: 10.14218/JCTH.2016.00052. Epub 2017 Feb 2.
8
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1.
Open Forum Infect Dis. 2016 Dec 27;4(1):ofw266. doi: 10.1093/ofid/ofw266. eCollection 2017 Winter.
9
Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
Transplantation. 2017 May;101(5):933-937. doi: 10.1097/TP.0000000000001611.
10
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
J Med Econ. 2017 Jul;20(7):692-702. doi: 10.1080/13696998.2017.1307204. Epub 2017 Apr 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验